Quantification of FLT3-ITD clones at diagnosis and relapse by HTS. (A) Σnorm-VAFs per sample at diagnosis and relapse, according to the treatment group. Only patients with a positive FLT3-ITD status by HTS at both diagnosis and relapse are displayed. (B) AR at diagnosis for lost and retained FLT3-ITD microclones and macroclones upon AML relapse, according to the treatment group. (C) Evolution of the AR of FLT3-ITD microclones detected at AML diagnosis. Each line features the evolution of a FLT3-ITD microclone between diagnosis and relapse. The threshold is positioned at an AR of 0.05. ∗, <.05; ∗∗∗, <.001. MUT, mutated; Pts, patients.